<DOC>
	<DOCNO>NCT00521586</DOCNO>
	<brief_summary>This study evaluate safety , tolerability immune response 13-valent pneumococcal conjugate vaccine ( 13vPnC ) trivalent inactivate flu vaccine ( TIV ) give together healthy adult age 50-59 year naive 23-valent pneumococcal polysaccharide vaccine ( 23vPS ) , vaccine give 1 month apart . It also evaluate immune response 13vPnC per year 4 year second dose 13vPnC give 5 year first dose .</brief_summary>
	<brief_title>Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Male female age 50 59 year Determined medical history , physical examination clinical judgement eligible study Able complete electronic diary Available 5 year 9 month duration study Previous vaccination license experimental pneumococcal vaccine Allergic egg proteins chicken protein History GuillianBarre syndrome Vaccination TIV within 6 month study start Vaccination diphtheriacontaining vaccine within 6 month study start Serious chronic disorder include immunodeficiency metastatic malignancy Known suspect hypersensitivity vaccine vaccine component</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Pneumococcal Conjugate Vaccine</keyword>
</DOC>